Meta-analysis of genome-wide associations and polygenic risk prediction for atrial fibrillation in more than 180,000 cases
- PMID: 40050429
- PMCID: PMC12094172
- DOI: 10.1038/s41588-024-02072-3
Meta-analysis of genome-wide associations and polygenic risk prediction for atrial fibrillation in more than 180,000 cases
Abstract
Atrial fibrillation (AF) is the most common heart rhythm abnormality and is a leading cause of heart failure and stroke. This large-scale meta-analysis of genome-wide association studies increased the power to detect single-nucleotide variant associations and found more than 350 AF-associated genetic loci. We identified candidate genes related to muscle contractility, cardiac muscle development and cell-cell communication at 139 loci. Furthermore, we assayed chromatin accessibility using assay for transposase-accessible chromatin with sequencing and histone H3 lysine 4 trimethylation in stem cell-derived atrial cardiomyocytes. We observed a marked increase in chromatin accessibility for our sentinel variants and prioritized genes in atrial cardiomyocytes. Finally, a polygenic risk score (PRS) based on our updated effect estimates improved AF risk prediction compared to the CHARGE-AF clinical risk score and a previously reported PRS for AF. The doubling of known risk loci will facilitate a greater understanding of the pathways underlying AF.
© 2025. The Author(s), under exclusive licence to Springer Nature America, Inc.
Conflict of interest statement
Competing interests: B.M.P. serves on the steering committee of the Yale Open Data Access Project funded by Johnson & Johnson. C.D.A. receives sponsored research support from Bayer AG and has consulted for ApoPharma. C. Haggerty receives research support from Tempus Labs, outside the scope of the present work. C.M.A. receives sponsored research support from St. Jude, Abbott and Roche. C.R. is supported by a grant from Bayer AG to the Broad Institute focused on the development of therapeutics for cardiovascular disease. C.R. is a full-time employee of GSK as of 1 July 2024. C.T.R. reports research grants through Brigham and Women’s Hospital from Amgen, Anthos, AstraZeneca, Daiichi Sankyo, Janssen, Merck and Novartis and has received honoraria for scientific advisory boards and consulting from Anthos, Bayer, Bristol Myers Squibb, Daiichi Sankyo, Janssen, Pfizer, Regeneron and Sirius. The spouse of C.W. works at Regeneron Pharmaceuticals. D.O.A., D.G., G. Sveinbjornsson, H.A., H.H., K.S., R.B.T. and U.T. are employees of deCODE genetics/Amgen. D.C. has received consultancy fees from Roche Diagnostics and Trimedics, and speaker’s fees from BMS/Pfizer and Servier, all outside of the current work. D.F.F. is a full-time employee of Bayer. E.B. performs uncompensated consultancies and lectures with The Medicines Company. E.-K.C. reports research grants or speaking fees from Abbott, Bayer, BMS/Pfizer, Biosense Webster, Chong Kun Dang, Daewoong Pharmaceutical, Daiichi Sankyo, DeepQure, Dreamtech, Jeil Pharmaceutical, Medtronic, Samjinpharm, Seers Technology and Skylabs. L.-C.W. receives sponsored research support from IBM to the Broad Institute. L.Z. is a full-time employee of Bayer AG. M.E.K. is employed by SYNLAB Holding Deutschland. M.S.S. receives research grant support through Brigham and Women’s Hospital from Abbott, Amgen, Anthos Therapeutics, AstraZeneca, Bayer, Daiichi Sankyo, Eisai, Intarcia, Ionis, Medicines Company, MedImmune, Merck, Novartis, Pfizer and Quark Pharmaceuticals and consults for Althera, Amgen, Anthos Therapeutics, AstraZeneca, Beren Therapeutics, Bristol Myers Squibb, DalCor, Dr. Reddy’s Laboratories, Fibrogen, Intarcia, Merck, Moderna, Novo Nordisk and Silence Therapeutics; additionally, M.S.S. is a member of the TIMI Study Group, which has also received institutional research grant support through Brigham and Women’s Hospital from ARCA Biopharma, Janssen Research and Development, Siemens Healthcare Diagnostics, Softcell Medical Limited, Regeneron, Roche and Zora Biosciences. N.A.M. reports involvement in clinical trials with Amgen, Pfizer, Ionis, Novartis and AstraZeneca without personal fees, payments or increase in salary. P.M.R. has received investigator-initiated research grant support for unrelated projects from NHLBI, Operation Warp Speed, Novartis, Kowa, Amarin and Pfizer and has served as a consultant on unrelated issues to Novo Nordisk, Flame, Agepha, Uppton, Novartis, Jansen, Health Outlook, Civi Biopharm, Alnylam and SOCAR. P.T.E. receives sponsored research support from Bayer AG, Bristol Myers Squibb, Pfizer and Novo Nordisk; he has also served on advisory boards or consulted for Bayer AG. S.A.L. is a full-time employee of Novartis Institutes for BioMedical Research as of 18 July 2022. Previously, S.A.L. received sponsored research support from Bristol Myers Squibb/Pfizer, Bayer, Boehringer Ingelheim, Fitbit, IBM, Medtronic and Premier, and consulted for Bristol Myers Squibb/Pfizer, Bayer, Blackstone Life Sciences and Invitae. S.M.D. receives research support from RenalytixAI and personal consulting fees from Calico Labs, outside the scope of the current research. W.M. reports grants and/or personal fees from Siemens Healthineers, Aegerion Pharmaceuticals, AMGEN, AstraZeneca, Sanofi, Alexion Pharmaceuticals, BASF, Abbott Diagnostics, Numares, Berlin-Chemie, Akzea Therapeutics, Bayer Vital, bestbion dx, Boehringer Ingelheim Pharma, Immundiagnostik, Merck Chemicals, MSD Sharp and Dohme, Novartis Pharma and Olink Proteomics, and other from Synlab Holding Deutschland, all outside the submitted work. A.N. is a consultant for Abbott, Biosrnse Webster, Biotronik, Boston Sci, iRhythm, Field Medical, Pulse Bioselect and Medtronic. S. Khurshid receives sponsored research support from Bayer AG. All other authors declare no competing interests.
References
-
- Chen Y-H et al. KCNQ1 gain-of-function mutation in familial atrial fibrillation. Science 299, 251–254 (2003). - PubMed
-
- Postma AV et al. A gain-of-function TBX5 mutation is associated with atypical Holt–Oram syndrome and paroxysmal atrial fibrillation. Circ. Res 102, 1433–1442 (2008). - PubMed
-
- Gudbjartsson DF et al. Variants conferring risk of atrial fibrillation on chromosome 4q25. Nature 448, 353–357 (2007). - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- 16EIA26410001/AHA/American Heart Association-American Stroke Association/United States
- R01 HL086694/HL/NHLBI NIH HHS/United States
- U01 HG004402/HG/NHGRI NIH HHS/United States
- P30 DK063491/DK/NIDDK NIH HHS/United States
- R01 HL111314/HL/NHLBI NIH HHS/United States
- 75N92021D00006/HL/NHLBI NIH HHS/United States
- R01 HL158071/HL/NHLBI NIH HHS/United States
- N01 HC085081/HL/NHLBI NIH HHS/United States
- N01 HC095160/HL/NHLBI NIH HHS/United States
- RC4 AG039029/AG/NIA NIH HHS/United States
- U01 HG007417/HG/NHGRI NIH HHS/United States
- K08 HL159346/HL/NHLBI NIH HHS/United States
- 75N92020D00002/HL/NHLBI NIH HHS/United States
- N01 HC085080/HL/NHLBI NIH HHS/United States
- R01 HL095080/HL/NHLBI NIH HHS/United States
- UL1 RR024989/RR/NCRR NIH HHS/United States
- R01 HL139731/HL/NHLBI NIH HHS/United States
- N01 HC095161/HL/NHLBI NIH HHS/United States
- 75N92020D00005/HL/NHLBI NIH HHS/United States
- N01 HC095168/HL/NHLBI NIH HHS/United States
- N01 AG012100/AG/NIA NIH HHS/United States
- I01 BX004821/BX/BLRD VA/United States
- UL1 RR025005/RR/NCRR NIH HHS/United States
- U01 AG009740/AG/NIA NIH HHS/United States
- U01 HL080295/HL/NHLBI NIH HHS/United States
- UL1 TR001079/TR/NCATS NIH HHS/United States
- 18SFRN34110067/AHA/American Heart Association-American Stroke Association/United States
- N01 HC095169/HL/NHLBI NIH HHS/United States
- N01 HC085082/HL/NHLBI NIH HHS/United States
- R01 HL092577/HL/NHLBI NIH HHS/United States
- R01 HL068986/HL/NHLBI NIH HHS/United States
- R01 HL059367/HL/NHLBI NIH HHS/United States
- U01 HL130114/HL/NHLBI NIH HHS/United States
- HHSN268200800007C/HL/NHLBI NIH HHS/United States
- N01 HC085086/HL/NHLBI NIH HHS/United States
- R01 HL085251/HL/NHLBI NIH HHS/United States
- 75N92020D00001/HL/NHLBI NIH HHS/United States
- N01 HC085083/HL/NHLBI NIH HHS/United States
- R35 HL161016/HL/NHLBI NIH HHS/United States
- 18SFRN34110082/AHA/American Heart Association-American Stroke Association/United States
- N01 HC095167/HL/NHLBI NIH HHS/United States
- N01 HC095159/HL/NHLBI NIH HHS/United States
- 75N92020D00003/HL/NHLBI NIH HHS/United States
- R01 HL090620/HL/NHLBI NIH HHS/United States
- R01 HL105756/HL/NHLBI NIH HHS/United States
- IK6 BX006185/BX/BLRD VA/United States
- HHSN268201200036C/HL/NHLBI NIH HHS/United States
- R01 NS103924/NS/NINDS NIH HHS/United States
- U01 NS069763/NS/NINDS NIH HHS/United States
- HHSN268201800001C/HL/NHLBI NIH HHS/United States
- HHSN268201700001I/HL/NHLBI NIH HHS/United States
- U01 NS069208/NS/NINDS NIH HHS/United States
- IK2 CX001780/CX/CSRD VA/United States
- P01 HL158502/HL/NHLBI NIH HHS/United States
- K24 HL148521/HL/NHLBI NIH HHS/United States
- 18SFRN34250007/AHA/American Heart Association-American Stroke Association/United States
- HHSN268201700004I/HL/NHLBI NIH HHS/United States
- U01 HG006380/HG/NHGRI NIH HHS/United States
- N01 HC085079/HL/NHLBI NIH HHS/United States
- UL1 TR001420/TR/NCATS NIH HHS/United States
- 75N92020D00004/HL/NHLBI NIH HHS/United States
- N01 HC095163/HL/NHLBI NIH HHS/United States
- 75N92020D00007/HL/NHLBI NIH HHS/United States
- HHSN268200782096C/HL/NHLBI NIH HHS/United States
- HHSN268201500003I/HL/NHLBI NIH HHS/United States
- 75N92019D00031/HL/NHLBI NIH HHS/United States
- K23 HL169839/HL/NHLBI NIH HHS/United States
- UL1 TR000040/TR/NCATS NIH HHS/United States
- RC2 AG036495/AG/NIA NIH HHS/United States
- R01 HL157635/HL/NHLBI NIH HHS/United States
- N01 HC095166/HL/NHLBI NIH HHS/United States
- HHSN268201700002I/HL/NHLBI NIH HHS/United States
- HHSN268201700005I/HL/NHLBI NIH HHS/United States
- N01 HC095162/HL/NHLBI NIH HHS/United States
- 75N92020D00006/HL/NHLBI NIH HHS/United States
- R01 AG023629/AG/NIA NIH HHS/United States
- R01 HL087641/HL/NHLBI NIH HHS/United States
- UL1 TR001881/TR/NCATS NIH HHS/United States
- R01 HL073410/HL/NHLBI NIH HHS/United States
- N01 HC095165/HL/NHLBI NIH HHS/United States
- N01 HC095164/HL/NHLBI NIH HHS/United States
- HHSN268201700003I/HL/NHLBI NIH HHS/United States
- HHSN271201200022C/DA/NIDA NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical
